Aktuellt
SENASTE
Redeye provides a short research update following the positive phase IIb results with lead candidate pudafensine published by Initiator Pharma last week. Overall, we are encouraged to learn that the candidate demonstrated statistically significant and clinically relevant efficacy. We raise our base case valuation to SEK24 as we see an increased likelihood of approval (LoA) following the results.
LÄS MER
